These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36668849)

  • 21. OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment.
    González-Quintanilla V; Evers S; Pascual J
    Handb Clin Neurol; 2024; 199():87-106. PubMed ID: 38307674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
    Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxins for the prevention of migraine in adults.
    Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
    Guerzoni S; Pellesi L; Baraldi C; Pini LA
    J Headache Pain; 2015; 17():48. PubMed ID: 27146068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
    Lyseng-Williamson KA; Frampton JE
    CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study.
    Altamura C; Brunelli N; Viticchi G; Salvemini S; Cecchi G; Marcosano M; Fofi L; Silvestrini M; Vernieri F
    Toxins (Basel); 2023 Apr; 15(4):. PubMed ID: 37104222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role.
    Grazzi L; Montisano DA; Rizzoli P; Guastafierro E; Marcassoli A; Fornari A; Raggi A
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
    Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
    J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
    J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
    Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
    Zandieh A; Cutrer FM
    BMC Neurol; 2022 Jun; 22(1):218. PubMed ID: 35698027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Lanteri-Minet M; Ducros A; Francois C; Olewinska E; Nikodem M; Dupont-Benjamin L
    Cephalalgia; 2022 Dec; 42(14):1543-1564. PubMed ID: 36081276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
    Artemenko AR; Abramov VG; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Yakovleva PN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(5):89-99. PubMed ID: 37315247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
    Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA.
    Alpuente A; Gallardo VJ; Torres-Ferrus M; Alvarez-Sabin J; Pozo-Rosich P
    Eur J Neurol; 2019 Dec; 26(12):1464-1470. PubMed ID: 31220392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
    Hansson-Hedblom A; Axelsson I; Jacobson L; Tedroff J; Borgström F
    J Headache Pain; 2020 Aug; 21(1):99. PubMed ID: 32787820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.